Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scorpion sting study tests simpler antivenom dosing

NCT ID NCT06333834

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two different ways of giving scorpion antivenom to adults who were stung. One group got a dose based on how severe their symptoms were, while the other group got the same dose for everyone. The goal was to see if the simpler approach works just as well at relieving symptoms. The trial involved 56 people and looked at how fast symptoms went away, side effects, and how much venom and antivenom was in the blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
scorpion antivenom
What this could lead to
If successful, this could show that a simpler, one-size-fits-all dose of antivenom works just as well as the current severity-based dosing, making treatment faster and easier.
What could go wrong
This is a small, completed Phase 2/3 trial with only 56 participants, so results may not apply broadly. The experimental dose may not be as effective in more severe cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

56 people

The number who actually took part.

Started

Jun 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals aged 18 or older presenting with a diagnosis of scorpionism to the emergency department. * Treated solely with paracetamol, scorpion antivenom, saline solution, and local ice application. * Any gender. * Less than two hours elapsed since scorpion sting. * Willing to participate in the study through written informed consent. Exclusion Criteria: * Allergies or contraindications to any of the study medications. * Uncertainty regarding scorpion sting. * Previous treatment by another physician. * Intramuscular administration of scorpion antivenom due to urgent clinical conditions. * Decision not to provide informed consent. * Any limitations hindering the proper understanding of study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Centruroides envenomation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

scorpion envenomation Scorpion Stings

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Servicios Médicos Municipales de San Pedro Tlaquepaque.

    Tlaquepaque, Jalisco, 45560, Mexico